Colgate-Palmolive (CL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended June 2026, Colgate-Palmolive (CL) reported revenue of $5.36 billion, up 4.9% over the same period last year. EPS came in at $0.99, compared to $0.92 in the year-ago quarter.

The reported revenue represents a surprise of +0.2% over the Zacks Consensus Estimate of $5.35 billion. With the consensus EPS estimate being $0.95, the EPS surprise was +4.21%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Colgate-Palmolive performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Sales- Oral, Personal and Home Care- North America: $891 million versus the four-analyst average estimate of $908.99 million. The reported number represents a year-over-year change of -13.2%.
• Net Sales- Oral, Personal and Home Care- Asia Pacific: $782 million compared to the $770.07 million average estimate based on four analysts. The reported number represents a change of +13.8% year over year.
• Net Sales- Oral, Personal and Home Care- Europe, Middle East & Africa: $1.12 billion compared to the $1.17 billion average estimate based on four analysts. The reported number represents a change of +51.9% year over year.
• Net Sales- Oral, Personal and Home Care- Latin America: $1.37 billion compared to the $1.33 billion average estimate based on four analysts. The reported number represents a change of +13.7% year over year.
• Net Sales- Pet Nutrition: $1.2 billion versus the five-analyst average estimate of $1.19 billion. The reported number represents a year-over-year change of +3.3%.
• Net Sales- Total Oral, Personal and Home Care: $4.17 billion versus the five-analyst average estimate of $4.17 billion. The reported number represents a year-over-year change of +5.4%.
• Operating profit- Pet Nutrition: $269 million versus $267.14 million estimated by three analysts on average.
• Operating profit- Total Oral, Personal and Home Care: $1.08 billion compared to the $1.04 billion average estimate based on three analysts.

View all Key Company Metrics for Colgate-Palmolive here>>>

Shares of Colgate-Palmolive have returned -3.7% over the past month versus the Zacks S&P 500 composite's -0.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research